Europe Channel Partners Apricus has Vitaros approved in Europe and Canada and works with partners Mylan, Takeda, Hexal, Recordati, Bracco, and Laboratoires Majorelle. Leverage these relationships to expand market access in additional European markets through licensing, co-promotion, or expanded distribution agreements.

Second Gen Vitaros The second generation room temperature Vitaros is under development, offering improved logistics and shelf stability to enable faster market entry and easier adoption by existing partners and new markets.

Pipeline Synergy The pipeline focuses on urology and rheumatology with fispemifene in Phase 2b for male secondary hypogonadism and RayVa in Phase 2a for Raynaud's; these programs present cross selling opportunities to clinicians and can be paired with licensing or co development deals to accelerate revenue.

Lean Commercial Model With a small team of 11-50 and revenue in the 1-10 million range, Apricus is well suited for targeted, partner led distribution and contract manufacturing deals with mid sized pharma seeking niche urology or ED assets, enabling rapid BD cycles.

Global Market Expansion The current geographic footprint includes Europe and Canada; opportunities exist to pursue additional regulatory filings and distributor partnerships in other regions, leveraging existing marketing partnerships to accelerate market access and sales growth.